TORONTO, ON / ACCESSWIRE / August 16, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the …
→ Google 번역
TORONTO, ON / ACCESSWIRE / August 16, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and …
→ Google 번역
Taro Pharmaceutical press release (TARO): Q2 Non-GAAP EPS of $1.09 beats by $0.24.Revenue of $156.7M (+6.5% Y/Y) beats by $6.8M.
→ Google 번역
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter ended June 30, 2022. Quarter ended June 30, 2022* Highlights ─ compared to June 30, 2021 Net sales increased $9.6 million, or 6.5%, to $156.7 million. Gross profit of $81.6 million (52.1% of net sales) compared to $77.7 million (52.8% of net sales).
→ Google 번역
Based on the current long-term trend, shares look like they will test long-term support. We expect support to hold there based on the company´s strong earnings power and clean balance sheet.
→ Google 번역
Taro Pharmaceutical press release (TARO): Q4 GAAP EPS of $0.73.Revenue of $143.26M (-3.4% Y/Y).
→ Google 번역
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2022. Quarter ended March 31, 2022 Highlights ─ compared to March 31, 2021 The quarter ended March 31, 2022, includes one month’s results from the February 28th acquisition of Alchemee. Net sales of $143.3 million
→ Google 번역
Taro Pharmaceutical Industries (TARO) shares closed 0.5% lower than its previous 52 week low, giving the company a market cap of $1B. The stock is currently down 26.9% year-to-date, down 47.9% over the past 12 months, and down 60.0% over the past five years. This week, the Dow Jones Industrial Average rose 1.8%, and the S&P 500 rose 1.4%. Trading Activity Trading volume this week was 105.3% higher than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -445.6% The company's stock price performance over the past 12 months lags the peer average by -421.7%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
→ Google 번역
The report on Global Urticaria Drug Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition []
→ Google 번역
Taro Pharmaceutical Industries (NYSE:TARO) released its quarterly earnings data on Wednesday. The company reported $0.86 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.01 by ($0.15), MarketWatch Earnings reports. Taro Pharmaceutical Industries had a positive return on equity of 10.36% and a negative net margin of 45.94%. Taro Pharmaceutical Industries […]
→ Google 번역
Stay up-to-date and exploit latest trends of Nasal Polyps Treatment Market with latest edition released by AMA. Nasal Polyps Treatment Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition of the worldwide Nasal Polyps Treatment
→ Google 번역
Taro Pharmaceutical Industries announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
→ Google 번역
Taro Pharmaceutical Industries announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
→ Google 번역
Taro Pharmaceutical Industries Ltd. (NYSE:TARO)’s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $63.93 and traded as low as $58.47. Taro Pharmaceutical Industries shares last traded at $58.47, with a volume of 28,440 shares. Several brokerages recently issued reports on TARO. ValuEngine […]
→ Google 번역
NEW DELHI: Hurt by one-time loss, leading drugmaker Sun Pharma reported a surprising loss during the June quarter while sales declined in all regions of the world the company operates in.However, the management hailed the company's performance. They said it has done well given the challenges it faced and managed to hold its market share in India and the US.How much did the company earn?Sun Pharma reported a loss of Rs 1,655.60 crore in the quarter, sharply lower from the expectation as it recognised an exceptional item. The company’s revenues from operations also fell to Rs 7,467.19 crore, from Rs 8,259.30 crore a year ago. EBITDA was at Rs 1,725 crores, with resulting EBITDA margin of 23.1 per cent.What is that exceptional item?The company reported a one-time loss of Rs 3,633.33 crore as it provided for settlement of legal cases involving two subsidiaries Taro Pharmaceuticals and Dusa Pharmaceuticals with the US government’s Department of Justice.What regions contributed the most to revenue?Company’s India sales were at Rs 2,388 crore, growing 3.2 per cent over the corresponding quarter last year.
→ Google 번역
Sun Pharmaceutical Industries has announced that one of the fully-owned subsidiaries of Taro Pharmaceutical Industries Ltd is about to to acquire Aquinox Pharmaceuticals (Canada) Inc for $8.2 milli…
→ Google 번역
Sun Pharmaceutical Industries on Wednesday said that a wholly-owned subsidiary of Taro Pharmaceutical Industries Ltd will acquire Aquinox Pharmaceuticals (Canada) Inc for $8.2 million.
→ Google 번역
On Wednesday, in a stock exchange filing, Sun Pharma said that a subsidiary of its American arm Taro Pharmaceutical will acquire Canada's Aquinox Pharmaceutical for $8.2 million (approx Rs 61.35 crore) in cash. Aquinox Pharmaceuticals is a corporation organised
→ Google 번역
Drug major Sun Pharma on Wednesday said a subsidiary of its American arm Taro Pharmaceutical will acquire Canada's Aquinox Pharmaceutical for USD 8.2 million (approx Rs 61.35 crore) in cash. 100 per cent shareholding, constituting equity shares and non-voting preferred shares, will be acquired, it said. A cash consideration of USD 8.2 million will be paid for acquisition of all shares of Aquinox Pharmaceutical, Sun Pharma said.
→ Google 번역
Sun Pharma stock trades higher than 20, 50, 100 and 200-day but lower than 5-day moving averages. Sun Pharma shares have risen 0.21% in one month and 12% since the beginning of the year 2020
→ Google 번역
New Delhi: Sun Pharma on Friday said its American arm Taro Pharmaceutical has resolved all cases involving multi-year investigations by US Department of Justice into the country's generic pharmaceutical industry. The US Department of Justice (DOJ) had launched investigations against the company over generic drug pricing. "Taro Pharmaceuticals USA, Inc, has resolved all cases involving the company in connection with the multi-year investigations by the DOJ, Antitrust Division and Civil Division, into the US generic pharmaceutical industry," Sun Pharma said in a regulatory filing. Under a deferred prosecution agreement reached with the DOJ, it said, adding that the department will file an information for conduct that took place between 2013 and 2015. Taro Pharmaceutical said, if the company adheres to the terms of the agreement, including the payment of USD 205.7 million (approx Rs 1,542 crore), the DOJ will dismiss the information at the end of a three-year period. "The company has also reached a framework understanding with the DOJ Civil Division, subject to final agreement and agency authorisation, in which the company has agreed to pay USD 213.3 million (approx Rs 1,599 crore) to resolve all claims related to federal healthcare programs," it added.
→ Google 번역
On Friday, shares of Sun Pharmaceutical Industries Limited rose 4 percent to Rs 497.80 in early trade after its US subsidiary, Taro Pharma reached a settlement agreement with the US Department of Justice (DoJ), Antitrust and Civil divisions to pay $205.7
→ Google 번역
Read more about Sun Pharma up 4% as US arm's Taro Pharma resolves antitrust investigation on Business Standard. Taro Pharma has reached a settlement agreement with the US Department of Justice, Antitrust and Civil divisions to pay more than $200 million to settle the generic drug price fixing allegations
→ Google 번역
Taro Pharmaceuticals (NYSE:TARO) says it agrees to pay ~$205M to settle allegations by the Department of Justice that it conspired to fix prices and rig bi
→ Google 번역
Taro Pharmaceutical Industries Ltd. announced today that its wholly-owned subsidiary, Taro Pharmaceuticals U.S.A., Inc. , has resolved all cases involving the Company in connection with the… | July 23, 2020
→ Google 번역
Record Annual Revenue of $22.3M Record Adjusted EBITDA of $7.0M up from $1.5M LAVAL, QC , March 18, 2020 /CNW/ - Crescita Therapeutics Inc. (TSX: CTX ) (GREY: CRRTF ) ("Crescita" or the "Company"), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development ("R&D") and manufacturing capabilities, today reported its financial results for the fourth quarter ("Q4-F2019") and fiscal year ended December 31, 2019 ("F2019"). All amounts are in thousands of Canadian dollars except for share and per share amounts, unless otherwise noted. Year-over-year Financial Highlights F2019 vs. F2018 Record revenue of $22,337 , an increase of $5,709 or 34.3%; Recognized $5,459 in up-front payments and guaranteed future minimum royalties related to the out-licensing agreement with Cantabria Labs (see below); Recognized $2,645 (US$2,000) in sales milestones from Taro related to the achievement of the final cumulative targets for the U.S. sales of Pliaglis®; Recognized a development milestone of $988 (US$750) from Taro related to the approval of an enhanced formulation of Pliaglis by the FDA (defined below); Operating expenses of $17,369 , an increase of $704 or 4.2%; Record Adjusted EBITDA 1 of $6,984 , an improvement of $5,533 versus $1,451 ; Repaid the Knight Loan in full in the amount of $3,570 (see below); Generated $4,249 in cash before repayment of the Knight Loan, resulting in closing cash position of $9,268 compared to $8,598 at the end of 2018.
→ Google 번역
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 2) Forty Seven Inc (NASDAQ: FTSV )( announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD )) IGM Biosciences Inc (NASDAQ: IGMS ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Karyopharm Therapeutics Inc (NASDAQ: KPTI )(announced positive late-stage results for selinexor) Passage Bio Inc (NASDAQ: PASG )(IPOed Friday) Syneos Health Inc (NASDAQ: SYNH ) Trillium Therapeutics Inc (NASDAQ: TRIL )(moved in sympathy with Forty Seven, as it has a similar drug in the pipeline for solid tumor) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 2) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akorn, Inc. (NASDAQ: AKRX ) ANI Pharmaceuticals Inc (NASDAQ: ANIP )(moved lower despite FDA nod for a generic version of Teva Pharmaceutical Industries Ltd's (NYSE: TEVA ) Alzheimer's related dementia drug) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) (reacted to its fourth-quarter results) Evolus Inc (NASDAQ: EOLS ) EXACT Sciences Corporation (NASDAQ: EXAS ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Imv Inc (NASDAQ: IMV ) Neurometrix Inc (NASDAQ: NURO ) Portola Pharmaceuticals Inc (NASDAQ: PTLA ) Precigen Inc (NASDAQ: PGEN ) Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) TherapeuticsMD Inc (NASDAQ: TXMD ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Viking Therapeutics Inc (NASDAQ: VKTX ) Related Link: How The COVID-19 Outbreak Is Benefiting Biotech Investors Stocks In Focus GenMark Starts Shipping COVID-19 Test Kits GenMark said it has begun shipping ePlex Research Use Only, or RUO, test kits to detect COVID-19 virus.
→ Google 번역
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 24) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) Co-Diagnostics Inc (NASDAQ: CODX )(received CE mark for its coronavirus test) COLLPLANT BIOTE/S ADR (NASDAQ: CLGN ) Gilead Sciences, Inc. (NASDAQ: GILD )(reacted to a statement from WHO that its experimental drug remdesivir could be the one drug that may have efficacy) NGM Biopharmaceuticals Inc (NASDAQ: NGM )( reacted to positive readout for its NASH drug) PAVmed Inc (NASDAQ: PAVM ) TELA Bio Inc (NASDAQ: TELA ) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Feb. 24) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) AngioDynamics, Inc. (NASDAQ: ANGO ) BioSig Technologies Inc (NASDAQ: BSGM ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Endologix, Inc.
→ Google 번역
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arcus Biosciences Inc (NYSE: RCUS ) BELLUS Health Inc (NASDAQ: BLU ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Masimo Corporation (NASDAQ: MASI ) (announced its fourth-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Relmada Therapeutics Inc (NASDAQ: RLMD ) Repro-Med Systems, Inc. (NASDAQ: KRMD ) Revance Therapeutics Inc (NASDAQ: RVNC ) (announced $287.5-million debt offering) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Feb. 13) Scpharmaceuticals Inc (NASDAQ: SCPH ) Soligenix, Inc.
→ Google 번역
Taro Pharmaceutical Industries Ltd ( NYSE: TARO) former Vice President of Sales and Marketing Ara Aprahamian has been indicted by the Justice Department for price-fixing and bid-rigging on Tuesday, Reuters reported . What Happened? According to the Justice Department , a federal grand jury in the US District Court for the Eastern District of Pennsylvania has indicted Aprahamian for his role to fix prices, rig bids, and allocate customers for generic drugs, and for making a false statement to federal agents who were investigating those conspiracies. Assistant Attorney General Makan Delrahim of the Department of Justice’s Antitrust Division said in the … Full story available on Benzinga.com
→ Google 번역
Taro Pharmaceuticals U.S.A., Inc., the U.S.-based business of Israeli Pharma firm Taro Pharmaceutical Industries, Ltd., recalled a certain lot of epilepsy and bipolar disorder medication Lamotrigine in the form of tablets for the potential cross-contamination, the U.
→ Google 번역
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating. Brokers have set a 1-year consensus price target of $110.00 for the company […]
→ Google 번역
Zacks Investment Research cut shares of Taro Pharmaceutical Industries (NYSE:TARO) from a hold rating to a sell rating in a report issued on Friday, Zacks.com reports. According to Zacks, “Taro Pharmaceutical Industries is engaged in the production, research and development, and marketing of prescription and over-the-counter pharmaceutical products, with a focus on generic products. In […]
→ Google 번역
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks
→ Google 번역
Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
→ Google 번역
Taro (TARO) delivered earnings and revenue surprises of -32.74% and -5.26%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
→ Google 번역
(Bloomberg Businessweek) -- You’d be hard-pressed to find someone who’s lost more during the recent upheaval in the generic drug business than Dilip Shanghvi: He forfeited $17 billion to be precise, plus the title of India’s richest man. After a four-year decline that erased 65% from the value of Sun Pharmaceutical Industries Ltd., the drugmaker he founded, Shanghvi is preparing to bounce back. He’s doing it by borrowing a page from Big Pharma’s playbook: investing in higher-margin patented medicines rather than relying solely on copying drugs. That won’t be easy, especially when the multinationals that dominate the pharmaceutical business have already seen the payoffs from their massive research and development spending become more uncertain. Those giants are increasingly turning to acquisitions to fill out their pipelines, and that’s where Shanghvi also sees an opening. Aided by an ability to move quickly because of Sun Pharma’s relatively small size—it had only about $4 billion in sales in 2018, compared with Pfizer Inc.’s $53.6 billion—and streamlined decision-making, Shanghvi thinks the company can eventually pick up enough early-stage innovations and key personnel to generate half its revenue from patented medicines. “It does require some additional skills beyond what a typical generic has,” Shanghvi says, but those skills aren’t impossible to acquire.
→ Google 번역